Annual EBITDA
-$542.46 M
+$98.03 M+15.31%
December 31, 2023
Summary
- As of February 7, 2025, RARE annual EBITDA is -$542.46 million, with the most recent change of +$98.03 million (+15.31%) on December 31, 2023.
- During the last 3 years, RARE annual EBITDA has fallen by -$402.65 million (-288.01%).
- RARE annual EBITDA is now -8188.16% below its all-time high of -$6.54 million, reached on December 31, 2011.
Performance
RARE EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$108.74 M
-$2.83 M-2.67%
September 30, 2024
Summary
- As of February 7, 2025, RARE quarterly EBITDA is -$108.74 million, with the most recent change of -$2.83 million (-2.67%) on September 30, 2024.
- Over the past year, RARE quarterly EBITDA has increased by +$25.40 million (+18.93%).
- RARE quarterly EBITDA is now -225.17% below its all-time high of $86.88 million, reached on December 31, 2018.
Performance
RARE Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$461.55 M
+$25.40 M+5.22%
September 30, 2024
Summary
- As of February 7, 2025, RARE TTM EBITDA is -$461.55 million, with the most recent change of +$25.40 million (+5.22%) on September 30, 2024.
- Over the past year, RARE TTM EBITDA has increased by +$86.02 million (+15.71%).
- RARE TTM EBITDA is now -10181.69% below its all-time high of -$4.49 million, reached on December 31, 2012.
Performance
RARE TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
RARE EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +15.3% | +18.9% | +15.7% |
| 3 y3 years | -288.0% | -78.5% | -49.9% |
| 5 y5 years | -205.5% | +1.6% | -18.4% |
RARE EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -32.2% | +15.3% | -7.3% | +50.5% | -12.5% | +28.1% |
| 5 y | 5-year | -288.0% | +15.3% | -391.2% | +50.5% | -230.1% | +28.1% |
| alltime | all time | -8188.2% | +15.3% | -225.2% | +50.5% | <-9999.0% | +28.1% |
Ultragenyx Pharmaceutical EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$108.74 M(+2.7%) | -$461.55 M(-5.2%) |
| Jun 2024 | - | -$105.92 M(-27.2%) | -$486.94 M(-6.2%) |
| Mar 2024 | - | -$145.54 M(+43.6%) | -$519.39 M(+0.6%) |
| Dec 2023 | -$542.46 M(-15.3%) | -$101.35 M(-24.4%) | -$516.45 M(-5.7%) |
| Sep 2023 | - | -$134.14 M(-3.0%) | -$547.56 M(-13.5%) |
| Jun 2023 | - | -$138.36 M(-3.0%) | -$633.04 M(-1.4%) |
| Mar 2023 | - | -$142.60 M(+7.7%) | -$642.00 M(+0.2%) |
| Dec 2022 | -$640.49 M(+56.1%) | -$132.45 M(-39.7%) | -$640.49 M(+2.8%) |
| Sep 2022 | - | -$219.62 M(+49.1%) | -$623.14 M(+34.2%) |
| Jun 2022 | - | -$147.33 M(+4.4%) | -$464.43 M(+8.7%) |
| Mar 2022 | - | -$141.09 M(+22.6%) | -$427.43 M(+4.2%) |
| Dec 2021 | -$410.32 M(+193.5%) | -$115.10 M(+88.9%) | -$410.32 M(+33.3%) |
| Sep 2021 | - | -$60.92 M(-44.8%) | -$307.83 M(+1.3%) |
| Jun 2021 | - | -$110.33 M(-11.0%) | -$303.77 M(+94.6%) |
| Mar 2021 | - | -$123.98 M(+883.2%) | -$156.10 M(+11.7%) |
| Dec 2020 | -$139.81 M(-64.1%) | -$12.61 M(-77.8%) | -$139.81 M(-35.0%) |
| Sep 2020 | - | -$56.86 M(-252.3%) | -$215.14 M(-20.0%) |
| Jun 2020 | - | $37.34 M(-134.7%) | -$268.83 M(-33.3%) |
| Mar 2020 | - | -$107.68 M(+22.4%) | -$403.03 M(+3.4%) |
| Dec 2019 | -$389.77 M(+119.5%) | -$87.94 M(-20.5%) | -$389.77 M(+81.3%) |
| Sep 2019 | - | -$110.56 M(+14.1%) | -$214.95 M(+13.3%) |
| Jun 2019 | - | -$96.85 M(+2.6%) | -$189.69 M(+4.4%) |
| Mar 2019 | - | -$94.42 M(-208.7%) | -$181.65 M(+2.3%) |
| Dec 2018 | -$177.56 M | $86.88 M(-201.9%) | -$177.56 M(-49.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$85.29 M(-4.0%) | -$348.15 M(+0.8%) |
| Jun 2018 | - | -$88.82 M(-1.7%) | -$345.48 M(+3.4%) |
| Mar 2018 | - | -$90.33 M(+7.9%) | -$334.05 M(+6.9%) |
| Dec 2017 | -$312.51 M(+27.8%) | -$83.72 M(+1.3%) | -$312.51 M(+4.8%) |
| Sep 2017 | - | -$82.62 M(+6.8%) | -$298.19 M(+6.4%) |
| Jun 2017 | - | -$77.39 M(+12.5%) | -$280.32 M(+7.7%) |
| Mar 2017 | - | -$68.79 M(-0.9%) | -$260.30 M(+6.4%) |
| Dec 2016 | -$244.58 M(+67.1%) | -$69.39 M(+7.2%) | -$244.58 M(+5.9%) |
| Sep 2016 | - | -$64.75 M(+12.9%) | -$230.87 M(+12.3%) |
| Jun 2016 | - | -$57.36 M(+8.1%) | -$205.61 M(+15.4%) |
| Mar 2016 | - | -$53.08 M(-4.7%) | -$178.13 M(+21.7%) |
| Dec 2015 | -$146.35 M(+160.9%) | -$55.68 M(+41.0%) | -$146.35 M(+36.3%) |
| Sep 2015 | - | -$39.49 M(+32.2%) | -$107.41 M(+28.5%) |
| Jun 2015 | - | -$29.88 M(+40.3%) | -$83.55 M(+24.4%) |
| Mar 2015 | - | -$21.30 M(+27.3%) | -$67.17 M(+19.8%) |
| Dec 2014 | -$56.09 M(+76.2%) | -$16.73 M(+7.0%) | -$56.09 M(+15.0%) |
| Sep 2014 | - | -$15.64 M(+15.9%) | -$48.78 M(+19.6%) |
| Jun 2014 | - | -$13.50 M(+32.1%) | -$40.79 M(+15.1%) |
| Mar 2014 | - | -$10.22 M(+8.6%) | -$35.44 M(+11.3%) |
| Dec 2013 | -$31.84 M(+103.1%) | -$9.41 M(+22.9%) | -$31.84 M(+18.3%) |
| Sep 2013 | - | -$7.66 M(-6.0%) | -$26.91 M(+39.8%) |
| Jun 2013 | - | -$8.14 M(+23.0%) | -$19.26 M(+73.3%) |
| Mar 2013 | - | -$6.62 M(+47.5%) | -$11.11 M(+147.5%) |
| Dec 2012 | -$15.67 M(+139.4%) | -$4.49 M | -$4.49 M |
| Dec 2011 | -$6.54 M | - | - |
FAQ
- What is Ultragenyx Pharmaceutical annual EBITDA?
- What is the all time high annual EBITDA for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical annual EBITDA year-on-year change?
- What is Ultragenyx Pharmaceutical quarterly EBITDA?
- What is the all time high quarterly EBITDA for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical quarterly EBITDA year-on-year change?
- What is Ultragenyx Pharmaceutical TTM EBITDA?
- What is the all time high TTM EBITDA for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical TTM EBITDA year-on-year change?
What is Ultragenyx Pharmaceutical annual EBITDA?
The current annual EBITDA of RARE is -$542.46 M
What is the all time high annual EBITDA for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high annual EBITDA is -$6.54 M
What is Ultragenyx Pharmaceutical annual EBITDA year-on-year change?
Over the past year, RARE annual EBITDA has changed by +$98.03 M (+15.31%)
What is Ultragenyx Pharmaceutical quarterly EBITDA?
The current quarterly EBITDA of RARE is -$108.74 M
What is the all time high quarterly EBITDA for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high quarterly EBITDA is $86.88 M
What is Ultragenyx Pharmaceutical quarterly EBITDA year-on-year change?
Over the past year, RARE quarterly EBITDA has changed by +$25.40 M (+18.93%)
What is Ultragenyx Pharmaceutical TTM EBITDA?
The current TTM EBITDA of RARE is -$461.55 M
What is the all time high TTM EBITDA for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high TTM EBITDA is -$4.49 M
What is Ultragenyx Pharmaceutical TTM EBITDA year-on-year change?
Over the past year, RARE TTM EBITDA has changed by +$86.02 M (+15.71%)